alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5360 Cohn fraction IV immunological test system. ( a ) *Identification.* A Cohn fraction IV immunological test system is a device that consists of or measures that fraction of plasma proteins, predominantly *alpha-* and *beta-* globulins, used as a raw material for the production of pure *alpha-* or *beta-* globulins. Measurement of specific *alpha-* or *beta-* globulins aids in the diagnosis of many diseases, such as Wilson's disease (an inherited disease affecting the liver and brain), Tangier's disease (absence of *alpha-*1-lipoprotein), malnutrition, iron deficiency anemia, red blood cell disorders, and kidney disease.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982; 47 FR 56846, Dec. 21, 1982, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38793, July 25, 2001]
#### § 822.16 What will you consider in the review of my submission?

First, we will determine that the submission is administratively complete. Then, in accordance with the law, we must determine whether the designated person has appropriate qualifications and experience to conduct the surveillance and whether the surveillance plan will result in the collection of useful data that will answer the surveillance question.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1996
<PERIOD-START>                             JUL-01-1995
<PERIOD-END>                               JUN-30-1996
<CASH>                                             532
<INT-BEARING-DEPOSITS>                           54838
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     194699
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                         909246
<ALLOWANCE>                                      11832
<TOTAL-ASSETS>                                 1269279
<DEPOSITS>                                      891304
<SHORT-TERM>                                    192101
<LIABILITIES-OTHER>                              21284
<LONG-TERM>                                      71418
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           300
<OTHER-SE>                                       92872
<TOTAL-LIABILITIES-AND-EQUITY>                 1269279
<INTEREST-LOAN>                                 131544
<INTEREST-INVEST>                                 9404
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                                140948
<INTEREST-DEPOSIT>                               45915
<INTEREST-EXPENSE>                               56818
<INTEREST-INCOME-NET>                            84130
<LOAN-LOSSES>                                     9044
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  22458
<INCOME-PRETAX>                                  69313
<INCOME-PRE-EXTRAORDINARY>                       69313
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     44160
<EPS-PRIMARY>                                   147.20
<EPS-DILUTED>                                   147.20
<YIELD-ACTUAL>                                   9.324
<LOANS-NON>                                      55282
<LOANS-PAST>                                     67298
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                  6137
<CHARGE-OFFS>                                     3385
<RECOVERIES>                                        36
<ALLOWANCE-CLOSE>                                11832
<ALLOWANCE-DOMESTIC>                             11832
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
Editorial Note on Part 60
Editorial Note: Nomenclature changes to part 60 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 60.26 Final action on regulatory review period determinations. ( a ) FDA will consider a regulatory review period determination to be final upon expiration of the 180-day period for filing a due diligence petition under § 60.30 unless FDA receives: ( 1 ) New information from PTO records, FDA records, or FDA centers that affects the regulatory review period determination;
( 2 ) A request under § 60.24 for revision of the regulatory review period determination;
( 3 ) A due diligence petition filed under § 60.30; or
( 4 ) A request for a hearing filed under § 60.40.
( b ) FDA will notify PTO that the regulatory review period determination is final upon: ( 1 ) The expiration of the 180-day period for filing a due diligence petition; or
( 2 ) If FDA has received a request for a revision, a due diligence petition, or a request for a hearing, upon resolution of the request for a revision, the petition, or the hearing, whichever is later. FDA will send a copy of the notification to the applicant and file a copy of the notification in the docket established for the application in FDA's Dockets Management Staff (HFA-305), 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
[53 FR 7305, Mar. 7, 1988, as amended at 59 FR 14364, Mar. 28, 1994]
<PAGE>

                                                                   Exhibit 10.19

Clyde L. Thomas and Kathleen Flanagan have entered into Change in Control
Agreements that are substantially identical in all material respects to the
agreement with Mr. Walsh that is incorporated by reference as Exhibit 10.18 to
the Annual Report on Form 10-K.

Steven F. Coleman and Colleen McKeown Adstedt have entered into Change in
Control Agreements that, as amended, are substantially identical in all material
respects to the Agreement and the amendment thereto filed as Exhibits 10.29 and
10.30, respectively, to the 2000 10-K.
# C_2015254EN.01002501.xml

| 3.8.2015 | EN | Official Journal of the European Union | C 254/25 |
| --- | --- | --- | --- |

3.8.2015

EN

Official Journal of the European Union

C 254/25

---

Order of the Civil Service Tribunal (Third Chamber) of 22 June 2015 — van Oudenaarden v Parliament

(Case F-139/14) (1)

1

((Civil Service - Officials - Annual leave - Carry over limited to 12 days - Compensation - Pension statement - Failure to contest within the time-limit - Lack of new material facts - Article 81 of the Rules of Procedure - Action manifestly inadmissible))

(2015/C 254/28)

Language of the case: French

Parties

Parties

Applicant: Annetje Elisabeth van Oudenaarden (Grevenmacher, Luxembourg) (represented by: F. Moyse, lawyer)

Applicant:

Defendant: European Parliament (represented by: M. Ecker and N. Chemaï, acting as Agents)

Defendant:

Re:

Re:

Application for annulment of the decision not to carry over to 2013 days of leave not taken by the applicant in 2012 due to illness and a claim for damages in respect of material and non-pecuniary harm allegedly suffered.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as manifestly inadmissble. |
| --- | --- |

1.

The action is dismissed as manifestly inadmissble.

| 2. | Ms van Oudenaarden and the European Parliament shall each bear their own costs. |
| --- | --- |

2.

Ms van Oudenaarden and the European Parliament shall each bear their own costs.

---

(1)  OJ C 89, 16.3.2015, p. 46.

1

---
EX-31Rule 13a-14(d)/15d-14(d) Certifications.

 

 

I,Anthony Sfarra, certify that:

 

1. Ihave reviewed this report on Form 10-K and all reports on Form 10-D required tobe filed in respect of the period covered by this report on Form 10-K of theWells Fargo Commercial Mortgage Trust 2015-C30 (the "Exchange Act periodicreports");

 

2.Based on my knowledge, the Exchange Act periodic reports, taken as a whole, donot contain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3. Basedon my knowledge, all of the distribution, servicing and other informationrequired to be provided under Form 10-D for the period covered by this reportis included in the Exchange Act periodic reports;

 

4.Based on my knowledge and the servicer compliance statements required in thisreport under Item 1123 of Regulation AB, and except as disclosed in theExchange Act periodic reports, the servicers have fulfilled their obligationsunder the servicing agreements in all material respects; and

 

5. Allof the reports on assessment of compliance with servicing criteria forasset-backed securities and their related attestation reports on assessment ofcompliance with servicing criteria for asset-backed securities required to beincluded in this report in accordance with Item 1122 of Regulation AB andExchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to thisreport, except as otherwise disclosed in this report. Any material instances ofnoncompliance described in such reports have been disclosed in this report onForm 10-K.

 

Ingiving the certifications above, I have reasonably relied on informationprovided to me by the following unaffiliated parties:

 

NationalCooperative Bank, N.A., as NCB Master Servicer, Rialto Capital Advisors, LLC, asSpecial Servicer, National Cooperative Bank, N.A., as NCB Special Servicer,Wilmington Trust, National Association, as Trustee, Pentalpha Surveillance LLC,as Trust Advisor, CoreLogic Solutions, LLC, as Servicing Function Participant,Computershare Trust Company, National Association, as Servicing FunctionParticipant for the Certificate Administrator, and Computershare Trust Company,National Association, as Servicing Function Participant for the Custodian.

 

 

Dated: March 14, 2024

 

 

/s/Anthony Sfarra

AnthonySfarra

President

(seniorofficer in charge of securitization of the depositor)
Exhibit 10.9(a)


 


Horace Mann Educators
Corporation (“HMEC”) and Horace Mann Service Corporation (“HMSC”) entered into severance agreements for
change of control with the following persons on the dates shown. These agreements are substantially similar to the one included
as Exhibit 10.13 to HMEC’s Annual Report on Form 10-K for the year ended December 31, 2012 except that the multiple of the
highest annual compensation received by the employee in the five preceding years used to determine a one-time cash payment is equal
to the duration listed below.


 


	 	 	Original	Replacement
	Employee	Duration	Agreement Date	Agreement Date
	 	 	 	 
	Bret A. Conklin	2 years	January 2002	December 2011
	Robert E. Rich	2 years	February 2001	December 2011


 


Last revision date: February 3, 2017
Editorial Note on Part 570
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 570.6 Opinion letters on food additive status. ( a ) Over the years the Food and Drug Administration has given informal written opinions to inquirers as to the safety of articles intended for use as components of, or in contact with, food. Prior to the enactment of the Food Additives Amendment of 1958 (Pub. L. 85-929, Sept. 6, 1958), these opinions were given pursuant to section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act, which reads in part: “A food shall be deemed to be adulterated if it bears or contains any poisonous or deleterious substance which may render it injurious to health”.
( b ) Since enactment of the Food Additives Amendment, the Food and Drug Administration has advised such inquirers that an article: ( 1 ) Is a food additive within the meaning of section 201(s) of the act; or
( 2 ) Is generally recognized as safe (GRAS); or
( 3 ) Has prior sanction or approval under that amendment; or
( 4 ) Is not a food additive under the conditions of intended use.
( c ) In the interest of the public health, such articles which have been considered in the past by the Food and Drug Administration to be safe under the provisions of section 402(a)(1), or to be generally recognized as safe for their intended use, or to have prior sanction or approval, or not to be food additives under the conditions of intended use, must be reexamined in the light of current scientific information and current principles for evaluating the safety of food additives if their use is to be continued.
( d ) Because of the time span involved, copies of many of the letters in which the Food and Drug Administration has expressed an informal opinion concerning the status of such articles may no longer be in the file of the Food and Drug Administration. In the absence of information concerning the names and uses made of all the articles referred to in such letters, their safety of use cannot be reexamined. For this reason all food additive status opinions of the kind described in paragraph (c) of this section given by the Food and Drug Administration are hereby revoked.
( e ) The prior opinions of the kind described in paragraph (c) of this section will be replaced by qualified and current opinions if the recipient of each such letter forwards a copy of each to the Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance (HFV-200), 7500 Standish Pl., Rockville, MD 20855, along with a copy of his letter of inquiry, on or before July 23, 1970.
( f ) This section does not apply to food additive status opinion letters pertaining to articles that were considered by the Food and Drug Administration to be food additives nor to articles included in regulations in this Subchapter E if the articles are used in accordance with the requirements of such regulations.
[41 FR 38644, Sept. 10, 1976, as amended at 54 FR 18281, Apr. 28, 1989; 57 FR 6476, Feb. 25, 1992]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary information extracted from the financial 
statements in the Company's Annual Report on Form 10-K for the year ended
December 31, 1996.
</LEGEND>
<MULTIPLIER>                                   1
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                     DEC-31-1996
<PERIOD-END>                          DEC-31-1996         
<CASH>                                  8,133,468       
<SECURITIES>                            1,949,039 
<RECEIVABLES>                          10,779,477 
<ALLOWANCES>                              221,000 
<INVENTORY>                               616,865 
<CURRENT-ASSETS>                       21,658,436 
<PP&E>                                    481,421 
<DEPRECIATION>                             75,048        
<TOTAL-ASSETS>                         30,243,378          
<CURRENT-LIABILITIES>                   3,722,513
<BONDS>                                         0
<PREFERRED-MANDATORY>                           0
<PREFERRED>                                     0
<COMMON>                                    3,452
<OTHER-SE>                             26,517,413        
<TOTAL-LIABILITY-AND-EQUITY>           30,243,378
<SALES>                                24,648,928
<TOTAL-REVENUES>                       25,309,977
<CGS>                                  16,248,469
<TOTAL-COSTS>                          16,248,469
<OTHER-EXPENSES>                        6,075,878
<LOSS-PROVISION>                                0
<INTEREST-EXPENSE>                              0
<INCOME-PRETAX>                         3,689,374
<INCOME-TAX>                            1,498,000
<INCOME-CONTINUING>                     2,191,374
<DISCONTINUED>                                  0
<EXTRAORDINARY>                                 0
<CHANGES>                                       0
<NET-INCOME>                            2,191,374
<EPS-PRIMARY>                                 0.31
<EPS-DILUTED>                                 0.31
        


</TABLE>
# C_2016068EN.01002701.xml

| 22.2.2016 | EN | Official Journal of the European Union | C 68/27 |
| --- | --- | --- | --- |

22.2.2016

EN

Official Journal of the European Union

C 68/27

---

Order of the General Court of 17 December 2015 — Murnauer Markenvertrieb v OHIM — Bach Flower Remedies (MURNAUERS Bachblüten)

(Case T-534/14) (1)

1

((Community trade mark - Opposition proceedings - Withdrawal of the opposition - No need to adjudicate))

(2016/C 068/35)

Language of the case: German

Parties

Parties

Applicant: Murnauer Markenvertrieb GmbH (Egelsbach, Germany) (represented by: F. Traub and D. Horst, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: D. Walicka, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM intervening before the General Court: Bach Flower Remedies Ltd (Wimbledon, United Kingdom) (represented by: A. Renck and M. Petersen, lawyers)

Other party to the proceedings before the Board of Appeal of OHIM intervening before the General Court:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 5 May 2014 (Case R 2041/2012-2) concerning opposition proceedings between Murnauer Markenvertrieb GmbH and Bach Flower Remedies Ltd.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate in the action. |
| --- | --- |

1.

There is no longer any need to adjudicate in the action.

| 2. | Murnauer Markenvertrieb GmbH and Bach Flower Remedies Ltd shall bear their own costs and shall each pay half of the costs incurred by the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM). |
| --- | --- |

2.

Murnauer Markenvertrieb GmbH and Bach Flower Remedies Ltd shall bear their own costs and shall each pay half of the costs incurred by the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM).

---

(1)  OJ C 351, 6.10.2014.

1

---
**Exhibit32.1**

**CERTIFICATIONPURSUANT TO****18 U.S.C. SECTION 1350,****AS ADOPTED PURSUANT TO****SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with theQuarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the periodended March 31, 2007 as filed with the Securities and Exchange Commission onthe date hereof (the “Report”), I, Robin Raina, Chief Executive Officer of theCompany, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of theSarbanes-Oxley Act of 2002, that:

1. The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2. The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.
| By:                     | /s/ Robin Raina |   |   |   |
|-------------------------|-----------------|--------|--------|--------|
|                    |            |   |   |   |
| Name:                   | Robin Raina     |   |   |   |
|                    |            |   |   |   |
| Chief Executive Officer |            |   |   |   |
|                    |            |   |   |   |
| May 21, 2007            |            |   |   |   |
|                         |                 |        |        |        |  |  |

 

 

----
**Exhibit 31.2**

**CERTIFICATION**

I, Richard J. Baum, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 
| Date: November 20, 2006 |   | /s/ Richard J. Baum     |   |   |
|-------------------------|--------|-------------------------|--------|--------|
|                    |   | Richard J. Baum         |   |   |
|                    |   | Chief Financial Officer |   |   |

 

----
EX-99
  CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

                          CERTIFICATION PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                          (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of W-J International,
Ltd. ("Company") on Form 10-QSB for the quarter ended December 31,
2002 as filed with the Securities and Exchange Commission ("Report"),
the undersigned, in the capacity and on the date indicated below,
hereby certifies pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 (18 U.S.C. Section 1350), that to his knowledge:

1.  The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.

A signed original of this written statement required by Section 906
has been provided to W-J International, Ltd. and will be retained by
W-J International, Ltd. and furnished to the Securities and Exchange
Commission or its staff upon request


Dated:  April 25, 2003                      By: /s/  Edward H. Webb
                                            Edward H. Webb, President